ENG/中
老虎證券
市场
行情
24/7新闻
产品
功能
经纪人
定投
CPF/SRS 投资
专栏
美股碎股
TigerAI
费用
综合账户
股票与ETF
期权、窝轮与牛熊证
期货
债券
基金超市
Cash Boost
股票与ETF
融资利率
活动
帮助
账户操作
如何开户
开户文件
账户类型
资金与转仓
入金
DDA快捷入金
出金
转入股票
转出股票
货币兑换
产品与交易
可交易产品
订单类型
交易规则
申报
融资融券
保证金与杠杆
风险管理
做空风险
基金超市
基金开户与交易
Cash Boost账户
Cash Boost 账户FAQ
如何开通 Cash Boost 账户
如何用Cash Boost 账户交易
如何绑定CDP证券账户
Tiger Boss Debit Card
常见问题
费用说明
如何充值
如何使用我的Debit card
账单报表
账单报表
股息(分红)
机构
Tiger Fund Management
机构服务
财富及资产管理人
自营交易机构
介绍经纪商
三方服务商
老虎API平台
登入
立即註冊
Toggle
美股
詳情
本頁面由Tiger Trade Technology Pte. Ltd.提供服務
生物科技指數ETF-iShares Nasdaq
199.54
-4.1800
-2.05%
盤後:
200.90
1.36
+0.68%
19:59 EST
成交量:
259.09萬
成交額:
5.24億
市值:
106.16億
市盈率:
31.61
高:
205.99
開:
203.93
低:
199.26
收:
203.72
52周最高:
222.29
52周最低:
159.68
股本:
5,320.00萬
流通股本:
5,320.00萬
量比:
1.40
換手率:
4.87%
股息:
0.35
股息率:
0.17%
每股收益(TTM):
6.31
每股收益(LYR):
35.34
淨資產收益率:
24.54%
總資產收益率:
0.10%
市淨率:
1.30
市盈率(LYR):
5.65
資料載入中...
總覽
公司
新聞資訊
公告
英硅智能(03696)與羅欣藥業(002793.SZ)達成 AI 製藥戰略合作,聚焦消化與代謝等慢性病創新藥研發
智通财经
·
11/13
不靠mRNA?Pumitamig能否打開BioNTech的新增長?
明星股动态
·
11/13
聯手默沙東推進癌症疫苗,Moderna能否打開新增長?
明星股动态
·
11/13
再生元製藥公司:Baloncibart持續四周降低心率反應並改善體位性症狀
美股速递
·
11/13
再生元製藥:Baloncibart 150毫克第8天使DeltaHR降低9.5次/分,但第29天療效未能維持
美股速递
·
11/13
再生元製藥:Baloncibart劑量至450毫克總體耐受良好,不良反應多為輕中度
美股速递
·
11/13
POTS二期試驗:首創NPR1阻斷抗體Baloncibart可降低體位性心率並改善體位性症狀
美股速递
·
11/13
再生元製藥:Baloncibart 450毫克第8天使Deltahr降低11.4 bpm,第29天降低7.4 bpm
美股速递
·
11/13
Vir Biotechnology因計劃出售股票而股價暴跌
路透中文
·
11/13
安進(AMGN)創新藥達唑達利貝治療乾燥綜合徵3期臨床試驗取得積極結果
金吾财讯
·
11/11
安進Dazodalibep聯合方案第48周達到主要終點,疾病活動度顯著下降
美股速递
·
11/11
安進公司用於治療舍格倫綜合徵的試驗性藥物達到了晚期臨床試驗的目標
路透中文
·
11/11
安進Dazodalibep在3期OASIZ-301試驗中達到主要終點。
智通财经
·
11/11
焦點-CAR-T臨床試驗中的死亡病例並未動搖狼瘡患者對治癒的希望
路透中文
·
11/11
福泰製藥:首席執行官Reshma Kewalramani減持1.19萬股,套現約630.71萬美元
南方财经网
·
11/11
argenx(ARGX)將斥資至多11.5億美元收購Unnatural Products 加碼大環肽技術
金吾财讯
·
11/09
再生元製藥:Cideb(Sirna)單次給藥使肝臟脂肪減少最高達80%,效果持續至36周
美股速递
·
11/09
AI製藥進入下半場,MegaStream以雙原生驅動創新藥研發
上观新闻
·
11/08
強生公司每日一次的口服藥在晚期臨床試驗中緩解了銀屑病關節炎的症狀
路透中文
·
11/07
諾華和諾和諾德的心臟病藥物臨床試驗失敗,令專家們百思不得其解
路透中文
·
11/07
更多
{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股,新股,港股,A股等全球金融理财产品。新加坡华人最信赖的在线投资平台,现在加入即享低费用,24/5 无时差炒美股投资理财!","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股,新股,港股,A股等全球金融理财产品。新加坡华人最信赖的在线投资平台,现在加入即享低费用,24/5 无时差炒美股投资理财!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/stock/IBB/news?page=2"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"IBB","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IBB\",,,,,undefined,":{"symbol":"IBB","market":"US","secType":"STK","nameCN":"生物科技指數ETF-iShares Nasdaq","latestPrice":199.54,"timestamp":1795208400000,"preClose":203.72,"halted":0,"volume":2590873,"hourTrading":{"tag":"盘后","latestPrice":200.9,"preClose":199.54,"latestTime":"19:59 EST","volume":25359,"amount":5065611.0972,"timestamp":1795222747886,"change":1.36,"changeRate":0.006816,"amplitude":0.007317},"delay":0,"changeRate":-0.02051835853131753,"floatShares":53200000,"shares":53200000,"eps":6.311863,"marketStatus":"休市中","change":-4.18,"latestTime":"11-20 16:00:00 EST","open":203.925,"high":205.99,"low":199.26,"amount":523803789.7671,"amplitude":0.033036,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":6.311863,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1795424400000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":203.72,"sharesOutstanding":49450000,"nav":203.6628,"aum":10733029560,"dividendRate":0.001735,"bidAskSpread":0,"preHourTrading":{"tag":"盘前","latestPrice":203.62,"preClose":203.72,"latestTime":"09:29 EST","volume":1025,"amount":208284.59199999998,"timestamp":1795184999999,"change":-0.1,"changeRate":-0.000491,"amplitude":0.011347},"postHourTrading":{"tag":"盘后","latestPrice":200.9,"preClose":199.54,"latestTime":"19:59 EST","volume":25359,"amount":5065611.0972,"timestamp":1795222747886,"change":1.36,"changeRate":0.006816,"amplitude":0.007317},"volumeRatio":1.3958627248686988,"impliedVol":0.3206,"impliedVolPercentile":0.992},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IBB\",,,,,undefined,":{"symbol":"IBB","floatShares":53200000,"roa":"0.10%","roe":"24.54%","lyrEps":35.344796,"volumeRatio":1.3958627248686988,"shares":53200000,"dividePrice":0.3463,"high":205.99,"amplitude":0.033036,"preClose":203.72,"low":199.26,"week52Low":159.68,"pbRate":"1.30","psRate":"255.40","week52High":222.29,"institutionHeld":0,"latestPrice":199.54,"eps":6.311863,"divideRate":0.001735,"volume":2590873,"delay":0,"ttmEps":6.311863,"open":203.925,"prevYearClose":168.77,"prevWeekClose":212.5,"prevMonthClose":217.61,"prevQuarterClose":210.53,"fiveDayClose":212.5,"twentyDayClose":207.74,"sixtyDayClose":214.8},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IBB\",params:#limit:5,,,undefined,":[{"date":"2026-09-15","symbol":"IBB","amount":0.011194,"announcedDate":"2026-09-14","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-09-15","defaultRemindTime":1789479000000,"name":"生物科技指数ETF-iShares Nasdaq","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-09-18","payableDate":"2026-09-15","currency":"USD","dateTimestamp":1789444800000,"payDate":"2026-09-18"},{"date":"2026-06-15","symbol":"IBB","amount":0.023774,"announcedDate":"2026-06-12","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-06-15","defaultRemindTime":1781530200000,"name":"生物科技指数ETF-iShares Nasdaq","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-06-18","payableDate":"2026-06-15","currency":"USD","dateTimestamp":1781496000000,"payDate":"2026-06-18"},{"date":"2026-03-17","symbol":"IBB","amount":0.121818,"announcedDate":"2026-03-16","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-03-17","defaultRemindTime":1773754200000,"name":"生物科技指数ETF-iShares Nasdaq","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-03-20","payableDate":"2026-03-17","currency":"USD","dateTimestamp":1773720000000,"payDate":"2026-03-20"},{"date":"2025-12-16","symbol":"IBB","amount":0.183099,"announcedDate":"2025-12-15","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-16","defaultRemindTime":1765895400000,"name":"生物科技指数ETF-iShares Nasdaq","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-19","payableDate":"2025-12-16","currency":"USD","dateTimestamp":1765861200000,"payDate":"2025-12-19"},{"date":"2025-09-16","symbol":"IBB","amount":0.082843,"announcedDate":"2025-09-15","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-09-16","defaultRemindTime":1758029400000,"name":"生物科技指数ETF-iShares Nasdaq","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-19","payableDate":"2025-09-16","currency":"USD","dateTimestamp":1757995200000,"payDate":"2025-09-19"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IBB\",market:\"US\",,,undefined,":[{"executeDate":"2016-12-22","recordDate":"2016-12-27","paymentDate":"2016-12-29","value":0.091903,"currency":"USD"},{"executeDate":"2017-03-24","recordDate":"2017-03-28","paymentDate":"2017-03-30","value":0.29898,"currency":"USD"},{"executeDate":"2017-06-27","recordDate":"2017-06-29","paymentDate":"2017-06-30","value":0.176803,"currency":"USD"},{"executeDate":"2017-09-26","recordDate":"2017-09-27","paymentDate":"2017-09-29","value":0.118654,"currency":"USD"},{"executeDate":"2018-06-26","recordDate":"2018-06-27","paymentDate":"2018-07-02","value":0.15606,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"IBB\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IBB\",pageSize:20,pageCount:2,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2683059578","title":"英硅智能(03696)與羅欣藥業(002793.SZ)達成 AI 製藥戰略合作,聚焦消化與代謝等慢性病創新藥研發","url":"https://stock-news.laohu8.com/highlight/detail?id=2683059578","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2683059578?lang=zh_tw&edition=fundamental","pubTime":"2026-11-13 16:32","pubTimestamp":1794558763,"startTime":"0","endTime":"0","summary":"智通财经APP讯,英硅智能 公布,公司的全资附属公司英硅智能科技(上海)有限公司近日与罗欣药业签署了战略合作协议。根据战略合作协议,双方拟围绕创新药研发建立长期战略合作关系,推动人工智能技术与疾病领域专业知识、研究数据及研发经验的深度融合,共同探索具有临床价值和开发潜力的创新药研发。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1522846.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0132","APXH","002793","BK1141","BK4588","BBP","QTOC","BK0001","BK4585","GDOC","CHAT","BK1191","BK1574","IBB","LFSC","VTHR","ARTY","01477","XLVI","SBIO","AIPO","BK0239","AGIX","PBE","BIOY","GSKH","03696","BK0201","WRND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1166768118","title":"不靠mRNA?Pumitamig能否打開BioNTech的新增長?","url":"https://stock-news.laohu8.com/highlight/detail?id=1166768118","media":"明星股动态","labels":["videos"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1166768118?lang=zh_tw&edition=fundamental","pubTime":"2026-11-13 11:26","pubTimestamp":1794540402,"startTime":"0","endTime":"0","summary":"","market":"hk","thumbnail":"https://news-video-sg.skytigris.cn/videos/covers/5502.webp","type":0,"news_type":0,"thumbnails":["https://news-video-sg.skytigris.cn/videos/covers/5502.webp"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"videos","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBB","MRNA","MRNY","MRNX","MRK","XPH","XBI","BNTX"],"isVideo":true,"video":{"duration":152,"video_url":"https://news-video-sg.skytigris.cn/videos/remotion/5502/render_5502_1794537596352.mp4","video_thumbnail":"https://news-video-sg.skytigris.cn/videos/covers/5502.webp","audio_url":"https://news-video-sg.skytigris.cn/videos/remotion/5502/tts/voiceover_31dee8d67070132ac542e444.mp3","isAI":true},"gpt_icon":0},{"id":"1106960109","title":"聯手默沙東推進癌症疫苗,Moderna能否打開新增長?","url":"https://stock-news.laohu8.com/highlight/detail?id=1106960109","media":"明星股动态","labels":["videos"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1106960109?lang=zh_tw&edition=fundamental","pubTime":"2026-11-13 09:54","pubTimestamp":1794534890,"startTime":"0","endTime":"0","summary":"","market":"nz","thumbnail":"https://news-video-sg.skytigris.cn/videos/covers/5476.webp","type":0,"news_type":0,"thumbnails":["https://news-video-sg.skytigris.cn/videos/covers/5476.webp"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"videos","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MRK","MRNX","XBI","MRNA","IBB","MRNY","BNTX"],"isVideo":true,"video":{"duration":137,"video_url":"https://news-video-sg.skytigris.cn/videos/remotion/5476/render_5476_1794534355062.mp4","video_thumbnail":"https://news-video-sg.skytigris.cn/videos/covers/5476.webp","audio_url":"https://news-video-sg.skytigris.cn/videos/remotion/5476/tts/voiceover_17d84d08a091f2557d0bad9e.mp3","isAI":true},"gpt_icon":0},{"id":"1123885845","title":"再生元製藥公司:Baloncibart持續四周降低心率反應並改善體位性症狀","url":"https://stock-news.laohu8.com/highlight/detail?id=1123885845","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1123885845?lang=zh_tw&edition=fundamental","pubTime":"2026-11-13 06:02","pubTimestamp":1794520959,"startTime":"0","endTime":"0","summary":"再生元制药公司宣布,Baloncibart能够在为期四周的时间内持续降低心率反应,同时改善体位性症状。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU0289739699.SGD","LU2362541513.USD","LU0114720955.EUR","BK4588","LU1917777945.USD","LU2089984988.USD","LU2106854487.HKD","LU0882574055.USD","LU2468319806.SGD","IBBQ","LU0889565916.HKD","BBH","LU0109394709.USD","LU2324357040.USD","LU2362540622.SGD","LU2023250504.SGD","LU0058720904.USD","IBB","REGN","TBXU","LU0053666078.USD","LU0823434740.USD","BK4585","LU0320765992.SGD","LU2362541273.HKD","LU2237438978.USD","LU0823434583.USD","LU0823416689.USD","LU1974910355.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1121446846","title":"再生元製藥:Baloncibart 150毫克第8天使DeltaHR降低9.5次/分,但第29天療效未能維持","url":"https://stock-news.laohu8.com/highlight/detail?id=1121446846","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1121446846?lang=zh_tw&edition=fundamental","pubTime":"2026-11-13 06:01","pubTimestamp":1794520888,"startTime":"0","endTime":"0","summary":"再生元制药公司旗下Baloncibart 150毫克剂量在第8天时可使DeltaHR下降9.5 bpm,然而该效果在第29天未能持续。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0289739699.SGD","LU2362541513.USD","REGN","BK4585","IBBQ","LU2362541273.HKD","LU0320765992.SGD","IBB","LU2237438978.USD","BK4588","LU0058720904.USD","LU0053666078.USD","LU1917777945.USD","BBH","LU2023250504.SGD","LU2089984988.USD","LU2468319806.SGD","TBXU","LU0114720955.EUR","LU0882574055.USD","LU2106854487.HKD","LU1974910355.USD","LU2362540622.SGD","LU0109394709.USD","LU0823416689.USD","LU0889565916.HKD","LU0823434583.USD","LU0823434740.USD","BK4139","LU2324357040.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1141477651","title":"再生元製藥:Baloncibart劑量至450毫克總體耐受良好,不良反應多為輕中度","url":"https://stock-news.laohu8.com/highlight/detail?id=1141477651","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1141477651?lang=zh_tw&edition=fundamental","pubTime":"2026-11-13 06:01","pubTimestamp":1794520877,"startTime":"0","endTime":"0","summary":"再生元制药公司公布的数据显示,Baloncibart在最高450毫克的剂量下总体耐受性良好,治疗中出现的不良事件大多为轻度或中度。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBBQ","LU2468319806.SGD","LU0058720904.USD","LU0823416689.USD","LU0053666078.USD","LU0114720955.EUR","LU0823434740.USD","LU2362541513.USD","LU1917777945.USD","LU2324357040.USD","BK4588","BK4139","LU0289739699.SGD","LU2106854487.HKD","LU2237438978.USD","LU2362541273.HKD","LU0882574055.USD","LU0109394709.USD","BBH","LU1974910355.USD","IBB","REGN","LU0823434583.USD","LU2023250504.SGD","LU0320765992.SGD","BK4585","LU2362540622.SGD","LU0889565916.HKD","LU2089984988.USD","TBXU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1185587745","title":"POTS二期試驗:首創NPR1阻斷抗體Baloncibart可降低體位性心率並改善體位性症狀","url":"https://stock-news.laohu8.com/highlight/detail?id=1185587745","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1185587745?lang=zh_tw&edition=fundamental","pubTime":"2026-11-13 06:01","pubTimestamp":1794520873,"startTime":"0","endTime":"0","summary":"POTS二期试验:首创NPR1阻断抗体Baloncibart可降低体位性心率并改善体位性症状","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBBQ","LU2468319806.SGD","LU0058720904.USD","LU0823416689.USD","LU0053666078.USD","LU0114720955.EUR","LU0823434740.USD","LU2362541513.USD","LU1917777945.USD","LU2324357040.USD","BK4588","BK4139","LU0289739699.SGD","LU2106854487.HKD","LU2237438978.USD","LU2362541273.HKD","LU0882574055.USD","LU0109394709.USD","BBH","LU1974910355.USD","IBB","REGN","LU0823434583.USD","LU2023250504.SGD","LU0320765992.SGD","BK4585","LU2362540622.SGD","LU0889565916.HKD","LU2089984988.USD","TBXU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1194152400","title":"再生元製藥:Baloncibart 450毫克第8天使Deltahr降低11.4 bpm,第29天降低7.4 bpm","url":"https://stock-news.laohu8.com/highlight/detail?id=1194152400","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1194152400?lang=zh_tw&edition=fundamental","pubTime":"2026-11-13 06:01","pubTimestamp":1794520870,"startTime":"0","endTime":"0","summary":"再生元制药公司公布的Baloncibart 450毫克剂量数据显示,第8天Deltahr指标下降11.4 bpm,第29天降幅则为7.4 bpm。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["REGN","LU1974910355.USD","LU2468319806.SGD","LU2089984988.USD","BBH","BK4585","LU2362541273.HKD","LU0058720904.USD","LU2362541513.USD","LU0053666078.USD","LU0823434740.USD","LU2362540622.SGD","LU2023250504.SGD","LU0882574055.USD","TBXU","LU1917777945.USD","BK4588","IBBQ","LU2237438978.USD","IBB","LU0114720955.EUR","LU0109394709.USD","LU0823416689.USD","LU2324357040.USD","LU0320765992.SGD","BK4139","LU2106854487.HKD","LU0889565916.HKD","LU0289739699.SGD","LU0823434583.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2683251008","title":"Vir Biotechnology因計劃出售股票而股價暴跌","url":"https://stock-news.laohu8.com/highlight/detail?id=2683251008","media":"路透中文","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2683251008?lang=zh_tw&edition=fundamental","pubTime":"2026-11-13 05:36","pubTimestamp":1794519419,"startTime":"0","endTime":"0","summary":"BUZZ-Vir Biotechnology因计划出售股票而股价暴跌11月12日-** Vir BiotechnologyVIR.O股价在盘后交易中暴跌15%,至10.30美元,因该公司寻求股权融资** VIR 宣布发行 (link) 股票,但未披露交易规模** 利瑞克(Leerink)、摩根士丹利(Morgan Stanley)和埃弗科(Evercore)担任联席簿记行** 周一,VIR股价飙升","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261112:nL3S46T248:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1732799900.SGD","BK4583","IBBQ","LU2112291526.USD","LU0557290698.USD","EVR","BK4535","IE00BSNM7G36.USD","LU0965509010.AUD","GILD","BK4127","IBB","IE00B775SV38.USD","LU1037948897.HKD","TMED","BK4588","IE0002270589.USD","LU0006306889.USD","LU2487616109.SGD","LU2089283258.USD","LU0965509283.SGD","LU0053666078.USD","IE00B19Z3581.USD","LU1244550577.SGD","BBH","MEDI","LU0971096721.USD","LU1074936037.SGD","BIB","TBXU","IE00BZ1G4Q59.USD","LU1066053197.SGD","VIR","KBWB","LU1732800096.USD","LU2133065610.SGD","BMED","SG9999015945.SGD","LU2065169927.USD","BK4534","IE00B3S45H60.SGD","LU0122379950.USD","LU0889565916.HKD","LU0795875169.SGD","BK4578","LU1674673428.USD","LU1244550221.USD","LU0965508806.USD","LU1839511570.USD","IAI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682307554","title":"安進(AMGN)創新藥達唑達利貝治療乾燥綜合徵3期臨床試驗取得積極結果","url":"https://stock-news.laohu8.com/highlight/detail?id=2682307554","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2682307554?lang=zh_tw&edition=fundamental","pubTime":"2026-11-11 21:30","pubTimestamp":1794403851,"startTime":"0","endTime":"0","summary":"金吾财讯 | 生物制药巨头安进 宣布,其创新药达唑达利贝在治疗干燥综合征的全球3期OASIZ-301临床试验中取得关键突破,两项主要给药方案均成功达到主要终点。作为目前全球首个在同类研究中同时改善全身疾病活动度与患者自述症状的3期临床试验,该成果后续有望填补该领域尚无FDA批准疗法的空白。分析人士指出,鉴于干燥综合征目前尚无有效获批治疗药物,达唑达利贝有望成为同类首创疗法,进一步丰富安进在免疫与炎症领域的创新产品矩阵。","market":"sh","thumbnail":"https://static.szfiu.com/news/20250107/ODI2NGE1NjlmODgxZDI1NzFmMmQ4ODQzNDA1OTI5NjU2Mg==.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/ODI2NGE1NjlmODgxZDI1NzFmMmQ4ODQzNDA1OTI5NjU2Mg==.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"308247","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BJJMRZ35.SGD","BK1574","LU0289739699.SGD","LU0320765992.SGD","IE00B4R5TH58.HKD","LU2242652126.USD","LU2089984988.USD","IE00B2B36J28.USD","BK4599","IE0009355771.USD","LU0122379950.USD","BK4566","BIB","LU1236620750.USD","TBXU","BK4585","IE00BJT1NW94.SGD","MDTX","SG9999001440.SGD","LU0889565916.HKD","06978","LNGR","IBB","LU0868494617.USD","PBE","BK4533","LU2112291526.USD","BBH","159992","LU0058720904.USD","LU1236620834.HKD","BMED","AMGN","LU2468319806.SGD","BK4581","BK4588","LU0109394709.USD","MEDX","PJP","LU1061106388.HKD","BK4139","LU2242646821.SGD","IE00BFTCPJ56.SGD","LU1023059063.AUD","PSYK","BK1161","IBBJ","IBBQ","BK4534","IE0002141913.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1138902712","title":"安進Dazodalibep聯合方案第48周達到主要終點,疾病活動度顯著下降","url":"https://stock-news.laohu8.com/highlight/detail?id=1138902712","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1138902712?lang=zh_tw&edition=fundamental","pubTime":"2026-11-11 21:06","pubTimestamp":1794402364,"startTime":"0","endTime":"0","summary":"安进公司宣布,Dazodalibep联合治疗方案在第48周成功触及主要终点,患者疾病活动度出现显著降低。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0289739699.SGD","IE00BFTCPJ56.SGD","LU0868494617.USD","AMGN","LU1236620750.USD","BK4585","IBBQ","LU2112291526.USD","LU0320765992.SGD","IE0009355771.USD","LU1236620834.HKD","IE00B2B36J28.USD","LU1983299246.USD","IBB","PBE","BK4533","BK4588","IE0002141913.USD","LU0058720904.USD","BBH","BK4581","LU1023059063.AUD","BIB","LU2089984988.USD","LU2468319806.SGD","PJP","TBXU","LU2242652126.USD","IE00B4R5TH58.HKD","BK4599","IE00BJJMRZ35.SGD","LU1057294990.SGD","LU1571399168.USD","BK4534","LU0109394709.USD","LU0122379950.USD","BK4566","LU0889565916.HKD","SG9999001440.SGD","LU2242646821.SGD","LU1061106388.HKD","IE00BJT1NW94.SGD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682430403","title":"安進公司用於治療舍格倫綜合徵的試驗性藥物達到了晚期臨床試驗的目標","url":"https://stock-news.laohu8.com/highlight/detail?id=2682430403","media":"路透中文","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2682430403?lang=zh_tw&edition=fundamental","pubTime":"2026-11-11 21:05","pubTimestamp":1794402357,"startTime":"0","endTime":"0","summary":"安进公司用于治疗舍格伦综合征的试验性药物达到了晚期临床试验的目标路透社11月11日-安进公司(AMGN.O)周三表示,在一项针对自身免疫性疾病——舍格伦综合征患者的晚期临床研究中,其试验性药物显示出能持续降低疾病活动度。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261111:nL3T46S0YF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1236620834.HKD","BK4585","LU0058720904.USD","AMGN","PBE","LU1571399168.USD","LU1057294990.SGD","LU2089984988.USD","IE00B2B36J28.USD","BK4139","LU2112291526.USD","IE00B4R5TH58.HKD","LU0122379950.USD","BK4534","SG9999001440.SGD","LU1236620750.USD","BK4599","IBB","PJP","LU1983299246.USD","BK4588","BK4581","BBH","IE0002141913.USD","LU2242652126.USD","LU0320765992.SGD","TBXU","LU0109394709.USD","IBBQ","BK4566","LU2242646821.SGD","IE00BFTCPJ56.SGD","IE00BJJMRZ35.SGD","LU0868494617.USD","LU1023059063.AUD","LU2468319806.SGD","BK4533","IE00BJT1NW94.SGD","LU0289739699.SGD","LU0889565916.HKD","LU1061106388.HKD","IE0009355771.USD","BIB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682304263","title":"安進Dazodalibep在3期OASIZ-301試驗中達到主要終點。","url":"https://stock-news.laohu8.com/highlight/detail?id=2682304263","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2682304263?lang=zh_tw&edition=fundamental","pubTime":"2026-11-11 21:00","pubTimestamp":1794402055,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IE00B4R5TH58.HKD","BK4533","PJP","IE00BFTCPJ56.SGD","LU2468319806.SGD","LU2112291526.USD","LU1236620750.USD","IE00BJT1NW94.SGD","AMGN","BK4566","LU2089984988.USD","IE00BJJMRZ35.SGD","SG9999001440.SGD","LU0289739699.SGD","BK4534","BK4581","BIB","LU1236620834.HKD","LU0122379950.USD","TBXU","BK4599","BBH","LU1571399168.USD","IE00B2B36J28.USD","BK4588","IE0009355771.USD","LU2242652126.USD","LU1057294990.SGD","LU1983299246.USD","BK4139","LU1023059063.AUD","PBE","LU0320765992.SGD","LU0889565916.HKD","LU0058720904.USD","LU0868494617.USD","LU0109394709.USD","IBB","BK4585","LU2242646821.SGD","LU1061106388.HKD","IE0002141913.USD","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682303010","title":"焦點-CAR-T臨床試驗中的死亡病例並未動搖狼瘡患者對治癒的希望","url":"https://stock-news.laohu8.com/highlight/detail?id=2682303010","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2682303010?lang=zh_tw&edition=fundamental","pubTime":"2026-11-11 19:01","pubTimestamp":1794394876,"startTime":"0","endTime":"0","summary":"约10%至15%的狼疮患者会过早死亡。她22岁时被确诊患有狼疮。CAR-T是一种已成功用于治疗血液癌症的个性化免疫疗法。目前约有150项临床试验正在探索CAR-T疗法治疗系统性红斑狼疮的可能性,此外还有许多针对重症肌无力、硬皮病、肌炎、多发性硬化症和僵人综合征的试验。百时美施贵宝公司也以患者出现暂时性炎症事件为由,暂停了其CAR-T治疗自身免疫性疾病的临床试验患者招募。舍特表示,诺华试验中的死亡事件让医生们一头雾水。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261111:nL3S46S0RV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1718418525.SGD","LU1196500208.SGD","IBBQ","LU2360032135.SGD","LU2896262040.SGD","IE00BN8TJ469.HKD","LU0965508806.USD","IE00B1BXHZ80.USD","LU0689472784.USD","LU1778281490.HKD","TBXU","SGXZ57979304.SGD","BMY","BBH","LU1929549753.HKD","MEDX","SG9999015978.USD","LU1059921491.USD","BIB","IBB","RXL","XLV","FTXH","TMED","LU2129689514.USD","BK4578","BMED","GILD","LU0210528500.USD","CABA","IYH","KYTX","LU1506573853.SGD","FHLC","JDOC","LU0456855351.SGD","LU0882574055.USD","IXJ","LU2471134523.USD","LU2430703178.SGD","JNJ","IE00B3T34201.USD","LU1221951046.USD","PJP","MEDI","VHT","TRUH","GDOC","IHE","LU2065171402.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682347434","title":"福泰製藥:首席執行官Reshma Kewalramani減持1.19萬股,套現約630.71萬美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2682347434","media":"南方财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2682347434?lang=zh_tw&edition=fundamental","pubTime":"2026-11-11 07:34","pubTimestamp":1794353676,"startTime":"0","endTime":"0","summary":"21财经11月11日电,福泰制药(VertexPharmaceuticalsInc.,纳斯达克:VRTX)首席执行官兼总裁ReshmaKewalramani提交Form4持股变动声明。11月6日,ReshmaKewalramani通过1笔交易合计减持11866股普通股,成交价格531.53美元,套现约630.71万美元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202611113927821959.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202611113927821959.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BIB","IE00B19Z9Z06.USD","IBB","LU2462157665.USD","BK4588","LU2089984988.USD","IDNA","IE00B19Z3B42.SGD","TBXU","VRTX","LU2236285917.USD","LU0823416689.USD","LU0432979614.USD","IE00B894F039.SGD","LU1093756168.USD","BK4567","LU0320765992.SGD","LU0061475181.USD","IE00BJJMRZ35.SGD","LU2362541273.HKD","BK4585","SG9999001176.SGD","LU1674673428.USD","LU1035775433.USD","IE00B19Z9P08.USD","GNMX","LU0058720904.USD","LU2362541513.USD","IBBQ","SG9999013999.USD","IE0002141913.USD","IE00BJT1NW94.SGD","IE0002270589.USD","LU1778281490.HKD","LU1069344957.HKD","PBE","LU1585245621.USD","LU1430594728.SGD","SG9999001176.USD","LU0256863811.USD","BK4532","LU2417539215.USD","BK4533","BK4139","IE0009355771.USD","LU0417517546.SGD","LU0889565916.HKD","LU2362540622.SGD","LU2237438978.USD","BBH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682805434","title":"argenx(ARGX)將斥資至多11.5億美元收購Unnatural Products 加碼大環肽技術","url":"https://stock-news.laohu8.com/highlight/detail?id=2682805434","media":"金吾财讯","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2682805434?lang=zh_tw&edition=fundamental","pubTime":"2026-11-09 17:13","pubTimestamp":1794215597,"startTime":"0","endTime":"0","summary":"交易完成后,UNP将成为argenx全资子公司,其位于美国加州圣克鲁斯的团队将继续主导肽发现工作。目前,该交易已获双方董事会批准,预计将于今年年底前正式完成。根据协议条款,该交易总潜在对价最高可达约11.5亿美元。argenx首席执行官Karen Massey表示,将UNP尖端的大环肽发现平台与其自身的抗体工程技术相结合,具有高度互补性。","market":"us","thumbnail":"https://static.szfiu.com/news/20210810/ZmFlOWFhNTNlYzgzMTc4NTEyNzIzMzYzNzY2.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/ZmFlOWFhNTNlYzgzMTc4NTEyNzIzMzYzNzY2.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"308109","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BFTCPJ56.SGD","LU1929549753.HKD","LU0689472784.USD","IE00BMG7P587.USD","TBXU","DOCK","LU0820561909.HKD","TRUI","IBB","HWAY","UNP","ARGX","IE00BJJMRZ35.SGD","FMED","SUPL","BK4532","IE00B29SXL02.USD","LU0738911758.USD","IE00BLSP4239.USD","IE00BJT1NW94.SGD","IE0002141913.USD","LU0302445910.USD","LU0661504455.SGD","BK4581","LU0354030511.USD","LU2463526074.USD","LU0390134368.USD","LU1983260115.SGD","IE0034235188.USD","LU0312595415.SGD","IYT","IE00BN8TJ469.HKD","IE00B4R5TH58.HKD","LU0251131958.USD","LU1551013425.SGD","LU1303367103.USD","IE00BBT3K403.USD","IE00BMG7P702.HKD","SHPP","IE00BMG7P926.USD","IE00BD4GTV84.USD","LU0820561818.USD","BILT","BK4588","TPOR","IE00BD4GTW91.USD","BK4016","LU1978683503.SGD","LU1861219969.SGD","LU0320765992.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1187584346","title":"再生元製藥:Cideb(Sirna)單次給藥使肝臟脂肪減少最高達80%,效果持續至36周","url":"https://stock-news.laohu8.com/highlight/detail?id=1187584346","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1187584346?lang=zh_tw&edition=fundamental","pubTime":"2026-11-09 05:08","pubTimestamp":1794172118,"startTime":"0","endTime":"0","summary":"再生元制药公司宣布,Cideb(Sirna)单次给药可实现肝脏脂肪最高减少80%,且该疗效维持至第36周。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0320765992.SGD","IBB","LU0109394709.USD","LU1917777945.USD","IBBQ","LU2237438978.USD","LU0823416689.USD","BBH","LU2089984988.USD","LU0823434583.USD","LU0289739699.SGD","LU0058720904.USD","LU2324357040.USD","BK4139","LU0114720955.EUR","LU0823434740.USD","LU2468319806.SGD","LU2362541273.HKD","LU0889565916.HKD","LU2023250504.SGD","REGN","LU0053666078.USD","LU1974910355.USD","LU2362541513.USD","TBXU","LU2106854487.HKD","BK4588","BK4585","LU2362540622.SGD","LU0882574055.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681584205","title":"AI製藥進入下半場,MegaStream以雙原生驅動創新藥研發","url":"https://stock-news.laohu8.com/highlight/detail?id=2681584205","media":"上观新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2681584205?lang=zh_tw&edition=fundamental","pubTime":"2026-11-08 16:17","pubTimestamp":1794125865,"startTime":"0","endTime":"0","summary":"由和铂医药与百图生科联合创立的AI创新药研发公司MegaStreamTechBio日前亮相“2026国际生物计算创新峰会。峰会期间,MegaStream与两家联合创立方共同举行战略合作协议签约仪式,标志着MegaStream以”AIDD3.0:AI×Bio双原生理念重塑药物发现范式的实质性落地。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202611083925629561.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202611083925629561.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["IBB","GSKH","WRND","AIPO","SBIO","GDOC","BK4588","01477","BK1574","QTOC","BIOY","BK1191","CHAT","AGIX","VTHR","PBE","BK4585","ARTY","LFSC","APXH","XLVI","BBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681184810","title":"強生公司每日一次的口服藥在晚期臨床試驗中緩解了銀屑病關節炎的症狀","url":"https://stock-news.laohu8.com/highlight/detail?id=2681184810","media":"路透中文","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2681184810?lang=zh_tw&edition=fundamental","pubTime":"2026-11-07 23:00","pubTimestamp":1794063633,"startTime":"0","endTime":"0","summary":"强生公司每日一次的口服药在晚期临床试验中缓解了银屑病关节炎的症状Padmanabhan Ananthan路透社11月7日-强生公司周六表示,在一项晚期临床试验中,其每日一次的口服药在缓解银屑病关节炎患者症状方面,比安慰剂更有效,这可能为该药物的适应症扩展提供支持。该试验招募了此前未接受过生物制剂治疗的活动性银屑病关节炎成人患者。服用Icotyde的患者在银屑病皮肤症状方面也显示出改善。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261107:nL3S46O025:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1989772923.USD","LU0289961442.SGD","IE00B19Z3581.USD","LU1236620750.USD","JNJ","AGNG","LU2756315664.SGD","GDOC","TBXU","BIB","RXL","VHT","IHE","LU1923622614.USD","GLAM","IBBQ","SG9999015952.SGD","AMGN","BMY","LU1244550577.SGD","FTXH","BBH","LU0310800379.SGD","LU0795875086.SGD","TRUH","IE0002141913.USD","LU0234572021.USD","IXJ","MEDX","PBE","LU2089284900.SGD","LU0456855351.SGD","ABBV","XLV","IE000BZT7R73.USD","LU2129689605.HKD","IBB","LU0965509010.AUD","LU2237443549.SGD","FHLC","LU2347655156.SGD","LU0640476718.USD","IE00BBT3K403.USD","LU1934455277.USD","PPH","LU2360032135.SGD","IYH","PJP","JDOC","BMED"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681983810","title":"諾華和諾和諾德的心臟病藥物臨床試驗失敗,令專家們百思不得其解","url":"https://stock-news.laohu8.com/highlight/detail?id=2681983810","media":"路透中文","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2681983810?lang=zh_tw&edition=fundamental","pubTime":"2026-11-07 22:50","pubTimestamp":1794063056,"startTime":"0","endTime":"0","summary":"约20.6%的患者因不良反应而停用佩拉卡森,而安慰剂组这一比例为7.5%。安进的III期试验结果预计于2028年初公布,而礼来的结果预计于2029年公布。哈佛大学布里格姆妇女医院的保罗·里德克博士是阐明炎症与心脏病之间联系的先驱,他于周六公布了诺和诺德公司抗炎药物ziltivekimab的临床试验结果。9月7日,诺和诺德根据独立数据监查委员会的建议,终止了另外两项针对心力衰竭和炎症患者评估ziltivekimab的晚期临床试验 ,该委员会认为这些试验不太可能成功。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261107:nL3T46O023:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B4R5TH58.HKD","BK4533","PJP","IE00BFTCPJ56.SGD","LU2468319806.SGD","LU2112291526.USD","LU1236620750.USD","IE00BJT1NW94.SGD","AMGN","BK4566","LU2089984988.USD","IE00BJJMRZ35.SGD","SG9999001440.SGD","LU0289739699.SGD","BK4534","BK4581","BIB","LU1236620834.HKD","LU0122379950.USD","TBXU","BK4599","BBH","LU1571399168.USD","IE00B2B36J28.USD","BK4588","IE0009355771.USD","LU2242652126.USD","LU1057294990.SGD","LU1983299246.USD","BK4139","LU1023059063.AUD","PBE","LU0320765992.SGD","LU0889565916.HKD","LU0058720904.USD","LU0868494617.USD","LU0109394709.USD","IONS","IBB","BK4585","LU2242646821.SGD","LU1061106388.HKD","IE0002141913.USD","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":2,"totalSize":200,"code":"91000000","status":"200"}]}}